MDM2, another transcriptional target of MYCN and poor prognosis factor of neuroblastoma [38] was slightly but significantly (p<6.5 10−7) increased by the 2 molecules whereas CCNE1, transcriptional target of MYCN identified in stage 4 neuroblastoma [40, 41], was strongly down-regulated by citalopram and escitalopram in B104, SH-SY5Y and Kelly cell lines and by citalopram in IMR32 cell line. This evidence concerns the gene MDM2 and neuroblastoma.